secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065184
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA
--------------------------------------------------------------------------------

- Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.
- Full-year 2025 net sales $822.3M (+2.9% reported); pro forma $811.9M (+4.1% constant currency).
- FY25 net loss $(92.2)M, improved from $(126.0)M; free cash flow $3.1M (ex-M6 restructuring).
- 2026 guidance: net sales $850-860M (~5.5% pro forma CC growth); adj. EBITDA $95-98M.
- Three-year targets (2026-28): 6.5-7.5% sales CAGR, mid-teens EBITDA margin by 2028, positive FCF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000119312526065184/0001193125-26-065184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000119312526065184/ofix-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer